- Japanese patent issuances facilitate commercialization of MCC
in Japan -
BELLEVILLE, ON, June 17 /PRNewswire-FirstCall/ - Bioniche Life
Sciences Inc. (TSX: BNC), a research-based, technology-driven
Canadian biopharmaceutical company, today announced the issuance of
a number of patents for its proprietary Mycobacterial Cell Wall-DNA
Complex (MCC) composition and its Oligonucleotide technology
platform.
The following is a list of the Bioniche MCC patent applications
that have been allowed or issued in the various international
jurisdictions:
1. "Composition and Method for Regulating Cell Proliferation and Cell
Death" granted in Japan as Patent # 4335435; and in Canada as
Patent # 2299548.
2. "Composition and Method for the Treatment of Bladder Cancer" granted
in Japan as patent # 4426067.
3. "Chemotherapeutic Composition and Method" granted in Japan as Patent
# 4380922; and has been allowed in Canada.
4. "Method for the Treatment of Inflammation": A "Notice of Decision to
Grant a Patent" has been received for the Japanese application.
About Mycobacterial Cell Wall-DNA Complex (MCC)
Mycobacterial Cell Wall-DNA Complex (MCC) is a patented cell
wall composition isolated from Mycobacterium phlei. MCC is a
bifunctional agent with a direct effect on cancer cells
(chemotherapeutic-like activity) as well as a stimulatory activity
on immune effector cells such as macrophages and monocytes. MCC is
a platform technology, offering opportunities to develop a range of
oncology and immune stimulatory applications in both humans and
animals.
The following is a list of the Bioniche Oligonucleotide patent
applications that has been allowed or issued in the various
international jurisdictions:
1. 'Therapeutically Useful Synthetic Oligonucleotides' granted in Europe
as EP Patent # 1867718 (validated in: Switzerland, Germany,
Denmark, Spain, France, Great Britain and Italy). This application
has also been granted in Israel as Patent # 150196.
2. "Modulation of FAS and FASL Expression" issued in the US as Patent
# 7662792.
3. "Oligonucleotide Compositions and Their Use to Induce Differentiation
of Cells" granted in Japan as Patent # 4460220; and in South Korea
as Patent # 913860.
4. "Conformation-Activity Relationship of Apoptosis-Inducing
Phosphodiester Oligonucleotides" granted in South Korea as Patent #
943567; and a "Notice of Decision to Grant a Patent" has been
received for the Japanese application.
5. "Therapeutically Useful Triethyleneglycol Cholesteryl
Oligonucleotides" granted in Japan as Patent # 4405259; and issued
in the U.S. as Patent # 7635686.
"The development and maintenance of our patent portfolio is an
important investment for the Company," said Graeme McRae, Chairman, President & CEO. "It
ensures long-term protection of products in the marketplace
following successful registration."
About the Oligonucleotide Technology Platform
In 2000, Bioniche announced the discovery of a new class of
molecules with potential anticancer activity, referred to by the
Company under the trademark, "Oligomodulator(TM)". This new class
of molecules with potential clinical anticancer activity and immune
modulating properties is composed of short non-antisense DNA
Oligonucleotides that appear to possess a range of novel
pharmacological activities. The Company has continued to develop
the Oligonucleotide technology platform in the areas of immune
stimulation and modulation.
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a research-based,
technology-driven Canadian biopharmaceutical company focused on the
discovery, development, manufacturing, and marketing of proprietary
products for human and animal health markets worldwide. The
fully-integrated company employs approximately 200 skilled
personnel and has three operating divisions: Human Health, Animal
Health, and Food Safety. The Company's primary goal is to develop
proprietary cancer therapies supported by revenues from marketed
products in human and animal health. For more information, please
visit www.Bioniche.com.
Except for historical information, this news release may contain
forward-looking statements that reflect the Company's current
expectation regarding future events. These forward-looking
statements involve risk and uncertainties, which may cause, but are
not limited to, changing market conditions, the successful and
timely completion of clinical studies, the establishment of
corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the
regulatory approval process, and other risks detailed from time to
time in the Company's ongoing quarterly and annual reporting.
SOURCE Bioniche Life Sciences Inc.